Five Prime therapeutics Inc. (NASDAQ:FPRX) has announced it has entered into a collaboration agreement with Bristol Myers Squibb Co (NYSE:BMY) for the discovery and development of immune-oncology therapies. Five Prime Therapeutics Inc. (NASDAQ:FPRX) shares after opening at $20.81 moved to $23.08 on last trade day and at the end of the day closed at $22.99. Company price to sales ratio in past twelve months was calculated as 3.03 and price to cash ratio as 0.70. Five Prime Therapeutics Inc. (NASDAQ:FPRX) showed a positive weekly performance of 40.18%.
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA based molecular diagnostics has shared detailed plans about its product pipeline based on its proprietary technology in a news release. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares advanced 0.48% in last trading session and ended the day on $6.22. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) return on equity ratio is recorded as -170.40% and its return on assets is -140.50%. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) yearly performance is 36.11%.
One stock that might be an intriguing choice for investors right now is Impax Laboratories Inc. (NASDAQ:IPXL). This is because this security in the Pharmaceutical industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Impax Laboratories Inc. (NASDAQ:IPXL) shares moved up 0.36% in last trading session and was closed at $27.91, while trading in range of $27.81 – $28.50. Impax Laboratories Inc. (NASDAQ:IPXL) year to date (YTD) performance is 11.02%.
Vanda Pharmaceuticals (NASDAQ:VNDA) Director Thomas Watkins sold 35,000 shares of the stock on the open market in a transaction dated Friday, March 14th. The stock was sold at an average price of $17.66, for a total transaction of $618,100.00. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) weekly performance is 17.61%. On last trading day company shares ended up $18.03. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) distance from 50-day simple moving average (SMA50) is 33.28%. Analysts mean target price for the company is $24.33.